ALLO

In the past six months, Allogene Therapeutics' stock (ALLO) decreased by 30.13% over six months and 20.85% over one month, though it showed a 21.01% year-to-date increase, trading between $1.04 and $4.46 over the past 52 weeks. Key events include a public offering in April 2026 raising approximately $187.9 million, Q1 2026 earnings in May 2026 reporting a net loss of $42.6 million, positive interim futility analysis for the ALPHA3 trial in May 2026 showing 58.3% MRD clearance, Q2 2026 earnings in August 2026 reporting a net loss of $42.7 million, FDA granting Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for cema-cel in July 2026, and the retirement of its Chief Financial Officer in September 2026.